

JONATHAN H. DAVIS
P.O. Box 14 Woods Hole, MA 02543
(617) 283-9288
jdavis@creativeantibodies.com

EDUCATION

Harvard Medical School

Boston, MA

Postdoctoral Fellow

- Selection, *in vitro* evolution, and structure of RNA in labs of **Jack Szostak** (Nobel Prize in Physiology or Medicine, 2009) and **Gerhard Wagner**.
- Results published in **PNAS**, **JACS**, and **RNA**

University of California, San Francisco

San Francisco, CA

Ph.D. in Biophysics

- Structural biology of proteins in lab of **David Agard**.
- Thesis topic: Solution structure, dynamics, and folding studies of ω -Conotoxin GVIA and α -lytic protease.
- Results published in **Nature**, **Biochemistry**, and **J. Biomolecular NMR**.

San Francisco Conservatory of Music

San Francisco, CA

Bachelor of Music, Cello

Reed College

Portland, OR

Bachelor of Arts, Music

University of Pennsylvania

Philadelphia, PA

Major in Physics and Astrophysics

PROFILE

Current Roles:

Chair of Scientific Advisory Board, Invenra, Inc. Madison, WI

Scientific

Consultant specializing in antibody discovery and development, bispecific antibody design and use, antibody optimization and engineering, library design and construction, *in vitro* selection, scaffold binder discovery and engineering, and lead identification.

Legal

Expert consultant for patent litigation in the broad area of antibody therapeutics and platforms, bispecific antibody therapeutics and platforms, and other biologic therapeutic modalities.

CONSULTING EXPERIENCE

Creative Antibodies, Madison, WI

Founder and Principal Consultant

2024 – Present

Consultant for over a dozen companies in past two years, from virtual start-ups to commercial-stage biopharmas. Tasks include: guide discovery programs, identify optimal platforms, evaluate candidate molecules, assess risks / rewards, design and engineer antibodies and antigens, help design screening funnel, evaluate and manage CROs and CDMOs.

Expert opinion and evaluation for patent litigation in the broad area of antibody and bispecific I.P. Analyze arguments, provide insights and opinions on wording and interpretation of patents and other documents, give scientific understanding from one with ‘skill in the art’.

MAJOR ACHIEVEMENTS

- **Designed and initiated project to assess “Plug-and-Play” capabilities of B-Bodies.** Results have shown that B-Bodies are truly Plug-and-Play, able to accept antibody variable domains from a wide variety of sources. *Publication in preparation.*
- **Designed and oversaw project to create high diversity naive human libraries** for use with *in vitro* selection methods such as phage or yeast display. *Libraries have been validated and perform as designed.*
- **Led Project to Create Optimized B-Body, a Bispecific Platform:** Developed novel approach to creating heterodimeric CH3 pairs to optimize the B-Body platform. Resulted in a platform that outperforms all others tested, from its plug-and-play bispecific capabilities in discovery to its extremely high production and robust biophysics in manufacturing. *Led to an issued US patent, and multiple projects in preclinical and clinical phases using the platform.*
- **Principal Designer of Combinectin, a novel anti-HIV1 Biotherapeutic:** Leadership role and primary protein engineer in the discovery and development of Combinectin, a four-component biologic targeting HIV-1 entry. Led team through the early discovery efforts, met and overcame numerous challenges in the construction of such a complex molecule, applied rigorous scientific standards to ensure the final molecule met success criteria. *Work has been published (multiple papers), presented at numerous international conferences. Drug is currently in phase 1 trials.*
- **Pharmaceutical Platform Development:** Initiated project and personally solved a long-standing problem in antibody engineering. Created the SEEDbody, a proprietary and robust heterodimeric Fc platform that can support the development of drug candidates in a wide range of

disease areas. First molecules generated from *in silico* designs exceeded final platform specifications. *Resulted in an issued patent family (e.g. US 8,871,912), several publications, and an invitation to speak in opening session at IBC Conference on Antibody Engineering, Dec. 2007 (San Diego, CA), and at other conferences.*

- **Initiated Development of a Novel Concept in Protein Scaffolds:** Initiated project to create a protein scaffold from a *de novo*-designed protein sequence. Created all designs, performed or oversaw all research, and produced several molecules that met mission-critical needs in the development of several advanced candidates. *Sole inventor on submitted utility patent.*
- **Designed and Created Release Assay for Drug Candidate:** Successfully designed a non-cell based release assay for an advanced biological therapeutic candidate. Potential savings of millions of dollars in manufacturing costs, because new assay is more reliable, and expensive batches of clinical material will not have to be destroyed due to error in cell-based assay.
- **Developed New Paradigms in Library Design.** Looking at scaffold library design from a fresh perspective, have designed new classes of libraries that will sample a far broader range of sequence and structure space. Have also developed a new approach to affinity maturation that will help stabilize the binders that emerge.
- **Designed successful murine heterodimeric Fc platform.** Engineered mouse IgG1 and IgG2a to allow the generation of bispecific IgGs with minimal risk of immunogenicity in mouse studies. *Results published in mAbs.*
- **Leadership in protein engineering at BMS.** Recognized authority in complex protein design at BMS. Led or co-led teams exploring different areas of protein engineering, including humanization, deimmunization, antibody engineering, and bispecific antibody technologies.

RESEARCH EXPERIENCE

Creative Antibodies, Madison, WI

Founder and Principal Consultant

2024 – Present

Invenra, Inc, Madison, WI

Chair, Scientific Advisory Board

2024 – Present

Invenra, Inc, Madison, WI

Vice President of Innovation and Strategy

2021 – 2024

Head of Innovation

2019 – 2021

- **Member of senior management, lead Protein Engineering, Bioprocess, and Innovation groups.**

- **Initiated several new platform and therapeutic programs.** Leads a therapeutic discovery effort, as well as major platform improvements.

- **Conceived of and initiated anti-viral efforts.** Proposed an innovative approach to designing anti-viral drugs that could not only treat current pandemic or endemic viruses, but also prevent novel threats from spreading. *Awarded significant US Government contract for discovery and development of molecules targeting three deadly viral pathogens.*

Bristol-Myers Squibb (Adnexus)

Principal Scientist in Protein Design

2008 - 2019

- **Leader in platform and technology development, and protein design, modeling, and engineering.** We work on all aspects of protein engineering and technology development, including library design, scaffold optimization, deimmunization, and selection technologies.
- **Led a new therapeutic discovery project from concept to optimization.** Led the drug design for Combinectin (see above, under Major Achievements).
- **Lead protein designer for numerous antibody and bispecific antibody projects.**
- **Novel uses of protein engineering.** Proposed a protein engineering approach to (non-antibody) programs that had not considered the possibility. New designs resulted in significant improvements in both stability and immunogenic risk.

EMD Serono Research Institute

Senior Scientist II in Protein Engineering

Rockland, MA

2007 - 2008

- **Group leader for emerging binder technologies.** After EMD and Serono merger, moved to former Serono site as a charter member of the Protein Engineering and Enabling Technologies department. Lead group (1 direct report plus 2 graduate student interns) to develop the platforms described above, to the point where they could be useful components of therapeutic molecules.

EMD Lexigen Research Center

Senior Scientist II in Structural Biology

Billerica, MA

2001 – 2007

- **Project leader for biological binder platform technologies.** Working in areas of protein modeling, molecular biology, and phage display to create new platforms for biological therapeutics, including the field of **antibodies**. Lead a project group with 7 members from various line functions. Has had great success in providing the Company with new platform technologies for biological therapeutic development.
- **Team member for several other oncology projects.** Provide designs for engineered versions of protein therapeutic candidates with improved biophysical properties.
- **Project leader for new oncology concept.** Proposed a biological drug candidate with potentially high value, directed research to achieve Proof of Principle.

- **Phage display with T7 and M13 phage.** Designed and performed selections against a wide variety of targets. Designed and created libraries for both phage platforms.
- **Molecular modeling and design.** Using Rosetta++, modified proteins to alter properties as desired.

Skills:

Thought leader in the field of bispecific antibodies, with internationally recognized expertise in the design of bispecific antibody therapeutics and platforms. Specializes in designing bispecifics that utilize or mimic existing biological processes and exploit the physical relationship of the targets.

Protein engineer with expertise in designing and optimizing biologics, specializing in bispecific and multi-specific antibody design, Fc engineering, antibody humanization, immunogenicity assessment and deimmunization, fusion proteins, scaffold library design and selection, and antibody optimization. 30 years hands-on experience conducting independent research in drug discovery, protein engineering, *in vitro* selection and evolution, and molecular biology.

Creative inventor and problem solver, applying a wide range of techniques and multidisciplinary experience in implementing new tools and approaches. Invented novel platform technologies and opened new areas of potential biological therapeutics.

Strategic outlook on research and development, approaching projects with an eye toward risk / reward, and balance of overall risk. Believes in the importance of advancing into new areas by both internal development and acquisition of cutting edge technologies, with an overall strategy of providing strength and breadth for the future pipeline. Always considers downstream needs such as manufacturability when screening or optimizing therapeutic candidates. Has extensive contacts in Academia which can evolve into fruitful academic partnerships through development of cross-disciplinary collaborations.

Specific skills include: **Bispecific antibody design** using traditional antibody domains and/or scaffolds or peptides; **Heterodimeric Fc Engineering** to design and optimize Fc domains that preferentially heterodimerize for use in therapeutic designs; **Antibody modeling and optimization**, to maximize favorable drug-like properties; **Humanization** of monoclonal antibodies; **Design and construction** of both nucleic acid and protein libraries; **Protein selection** using M13 and T7 **phage display**; nucleic acid aptamer selection using **SELEX**; structural **NMR** of proteins and nucleic acids; **Molecular modeling** using **Rosetta++**, **MOE**, and **PyMol**; **protein engineering**; plasmid design; **Deimmunization** of proteins; synthetic biology; molecular biology, nucleic acid manipulation; bacterial protein expression and purification; biophysical characterization of macromolecules.

Experience in a broad range of therapeutic areas, including **virology, oncology, autoimmunity, gene therapy, and cardiovascular disease.** Has worked to develop bispecific molecules that modulate immune effector cells by manipulating natural pathways. Works at the interface of protein engineering and biology, to design effective therapeutics informed by the specific biological aim.

Expectations for the future: To help multiple companies perform discovery and innovative research to design first-in-class therapeutics including bispecific antibodies, implement new disruptive platforms and technologies for the next generation of biological therapeutics, improve existing therapeutic candidates through sophisticated protein engineering, and solve problems encountered during drug development. Ultimate goal is to expand the horizons of biotherapeutics through protein engineering, designing drugs that address unmet medical needs, and lead to a better understanding of protein construction and function.

Harvard Medical School / Mass. General Hospital
Post Doctoral Fellow

Boston, MA
1996 – 2001

Department of Molecular Biology, Mass. General Hospital and Howard Hughes Medical Institute.
Primary research advisor **Jack W. Szostak**, Ph.D.

Concurrently with Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School. Research advisor for NMR structural work **Gerhard Wagner**, Ph.D.

- ***In vitro* selection (SELEX) and structural analysis of RNA aptamers.** Devised methods for isolating stronger binders, validated methods through selection of low nanomolar binders to GTP. Explored how structured RNAs bind ligands, through NMR studies of GTP aptamers. Further explored the relationship between RNA complexity and functional fitness through detailed analysis of selected sequences.

- **Invented method for creating Green Fluorescent RNA.** Concept is to select RNA aptamers targeting environmentally sensitive dyes, that upon binding, boost fluorescence or change the spectral characteristics sufficiently to serve as an intracellular reporter. Reduction to practice incomplete due to change in employment. *Provisional patent submitted.*

University of California, San Francisco
Graduate Student

San Francisco, CA
1988 – 1996

Graduate Group in Biophysics, and Howard Hughes Medical Institute. Thesis advisor **David A. Agard**, Ph.D.

- **Protein structure determination.** Used 2-dimensional homonuclear NMR to solve the structure of ω -conotoxin GVIA.

- **Pioneered the use of triple-resonance NMR at UCSF.** Determined complete backbone NMR assignments of α -Lytic Protease, (α -LP), a 20 kDa serine protease.
- **Protein dynamics studies.** Analyzed the backbone dynamics of α -LP to address questions about the relationship between flexibility and specificity.
- **Protein folding studies.** Used hydrogen/deuterium exchange rate analysis to probe the folding and unfolding of α -LP under a range of conditions, to help understand its unusual folding pathway.

University of California, San Francisco
Research Associate, Dept. of Laboratory Medicine
 Directed by Mack Fulwyler, Ph.D.

San Francisco, CA
 1986 – 1988

- **Coating pancreatic islets.** Invented device for coating pancreatic islets in a thin layer of agarose.
- **Modified cell sorter.** Re-engineered a cytometer to analyze and sort very large particles, such as adipocytes.

INVITED CONFERENCE PARTICIPANT

December 2007 Oral presentation in the opening session of the IBC international conference on *Antibody Engineering*, San Diego

June 2008 Oral presentation at *Recombinant Antibodies* in Dublin, Ireland

August 2008 Oral presentation in the Antibody Summit at *Drug Discovery Technologies* in Boston

September 2009 Session Chair, Speaker, and member of Advisory Board for *Beyond Antibodies / Protein Engineering and Design*, San Diego

June 2010 Session Chair and member of Advisory Board for *Beyond Antibodies / Protein Engineering and Design*, San Francisco

June 2011 Session Chair, Speaker, and member of Advisory Board for *Beyond Antibodies / Protein Engineering and Design*, San Francisco

September 2011 Conference Chair for *World Bispecific Antibody Summit*, Boston

June 2014	Conference Chair for <i>Next Generation Protein Therapeutics</i> , San Francisco, CA
September 2014	Conference Chair for 5 th annual <i>World Bispecific Antibody Summit</i> , Boston
June 2015	Session Chair for <i>Next Generation Protein Therapeutics</i> , San Francisco
September 2015	Panelist at <i>World Bispecific Antibody Summit</i> , Boston
March 2016	Oral presentation at <i>Keystone Symposium on Antibodies as Drugs</i> , Whistler, BC, Canada
March 2016	Oral presentation at <i>Gordon Conference on Antibody Biology and Engineering</i> , Galveston
April 2016	Oral presentation at <i>PEGS</i> , Boston, MA
June 2016	Featured Speaker and Session Chair for <i>Next Generation Protein Therapeutics</i> , San Francisco
September 2016	Oral presentation and Session Chair for <i>World Bispecific Antibody Summit</i> , Boston
December 2016	Conference co-chair for <i>Computational Drug Development for Biologics</i> , Boston
May 2017	Invited speaker for <i>PEGS</i> , Boston, MA
July 2017	Oral presentation for <i>3rd Annual Conference on Peptides</i> , London, UK
September 2017	Oral presentation and Co-Chair for <i>World Bispecific Antibody Summit</i> , Boston, MA
October 2017	Oral presentation for <i>European Antibody and World Immunotherapy Congress</i> , Basel, Switzerland
December 2017	Co-presenter, pre-conference workshop on Designing and Optimizing Biologics for <i>Computational Drug Design for Biologics</i> , Boston
September 2019	Oral presentation at <i>World Bispecific Antibody Summit</i> , Boston
October 2019	Oral presentation for <i>European Antibody and World Immunotherapy Congress</i> , Basel, Switzerland
October 2019	Oral presentation for <i>Drug Discovery and Innovation</i> , San Francisco
December 2019	Oral presentation for <i>Antibody Engineering and Therapeutics</i> , San Diego
February 2020	Oral presentation for <i>Antibody Engineering and Therapeutics Asia</i> , Kyoto
March 2020	Oral presentation for <i>Festival of Biologics</i> , San Diego
May 2020	Oral presentation for <i>PEGS</i> , Virtual
June 2020	Oral presentation for <i>Antibody Engineering and Therapeutics</i> , Virtual
September 2020	Oral presentation for <i>World Bispecific</i> , Virtual
October 2020	Oral presentation for <i>Precision in Drug Discovery and Preclinical</i> , Virtual

March 2021	Oral presentation for <i>Festival of Biologics</i> , Virtual
September 2021	Oral presentation and session chair for <i>World Bispecific Virtual Conference</i>
December 2021	Oral presentation for <i>Antibody Engineering and Therapeutics</i>
December 2021	Chair for <i>Cytokine Immunotherapy Summit</i> , Boston
March 2022	Oral presentation for <i>Festival of Biologics</i> , San Diego
April 2022	Oral presentation for <i>Keystone Symposium on Antibodies</i> , Colorado
May 2022	Oral presentation for <i>PEGS</i> , Boston
May 2022	Oral presentation for <i>Treg Directed Therapeutics</i> , Boston
July 2022	Oral presentation for <i>Cytokine Targeted Therapies Summit</i> , Boston
September 2022	Oral presentation for <i>World Bispecific</i> , Boston
September 2022	Oral presentation for <i>The Antibody Series</i> , Porto
October 2022	Oral presentation for <i>Immunotherapy</i> , Boston
December 2022	Oral presentation for <i>Antibody Engineering and Therapeutics</i>
March 2024	Invited Keynote Panelist and session chair for <i>Festival of Biologics</i> , San Diego
May 2024	Session chair for <i>Keystone Symposium on Antibodies</i> , Colorado
February 2026	Oral presentation for <i>World ADC</i> , London, UK
March 2026	Oral presentation for <i>BioChina</i> , Suzhou, China

HONORS AND AWARDS

1997–99	NSRA fellowship from the National Institutes of Health
1997–98	MGH fund for Medical Discovery Fellowship
1991–93	Biotechnology Grant Fellowship
1989–91	Regents' Fellowship, University of California
1988–89	Full Fellowship, UCSF Biophysics Group

LEADERSHIP AND SUPERVISORY EXPERIENCE

- **Supervisory experience.** Supervised up to 4 direct reports, and teams of up to 12.
- **Team leader for technology groups.** Lead or co-lead several cross-site teams that meet regularly to advance various issues and technologies relating to protein engineering.
- **2009-2012: Program co-lead.** Co-lead a cross-functional and inter-site team ranging from 12 to 15 members, focused on the development of a novel and highly engineered multifunctional biotherapeutic.
- **Post-Doctoral period:** Supervised six starting graduate/rotation students during 1999–2000.

- **Symphony Orchestra Founder and Director:** Founded the UCSF Orchestra, and served as Conductor and Music Director for six years. The group consisted of 50–70 members. Organized and oversaw the growth, fundraising, and administration of the group, as well as attending to all the details necessary to maintain a successful performing orchestra. Group still ongoing (renamed *Symphony Parnassus*) after over 30 years.

TEACHING EXPERIENCE

- **Adjunct Associate Professor**, *Northeastern University*, Boston, MA. Currently a member of a team teaching courses in analytical protein methods in the Masters program in biotechnology.
- **Adjunct Professor**, *Wentworth Institute of Technology*, Boston, MA. Taught introductory physics in the Spring of 2000. Was in full charge of my section, gave all lectures, wrote all exams, and ran the lab.
- **Teaching Assistantships** for a graduate level cellular biophysics course in 1990, and a pharmacy school physical chemistry course in 1991, while at UCSF.

PUBLICATIONS

1. J. Davis ***Comprehensive Medicinal Chemistry IV*** (2026) Bispecifics: The future of therapeutic antibodies. Chapter.
2. Y. Benitex, J. Davis, et al. ***J. Applied Bioanal.*** (2021) Utility of LC-MS Surrogate Peptide Methodology in the Development of a Combninectin, a Unique Anti-HIV Biologic Drug. **7(3)**
3. F. Wang, J.C. Tsai, J.H. Davis, et al. ***Mabs*** (2020) Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.
4. D. Wensel, Y. Sun, J.H. Davis, et al. ***J. Virol.*** (2019) GSK3732394: a Multi-specific Inhibitor of HIV Entry. **93**
5. D. Wensel, Y. Sun, J.H. Davis, et al. ***J. Virol.*** (2018) A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity is Highly Synergistic when Linked to a CD4-Binding Adnectin. **92**
6. D. Wensel, Y. Sun, ... & J.H. Davis ***Antimicrob Agents Chemother.*** (2017) Discovery and characterization of a novel CD4-binding adnectin with potent anti-HIV activity, **61**
7. C. Chaudhry, J. Davis, et al. ***Anal Biochem.*** (2016) Building homogeneous time-resolved fluorescence resonance energy transfer assays for characterization of bivalent inhibitors of an inhibitor of apoptosis protein target, **497** 8-17.
8. I.C. Severin, A.L. Souza, J.H. Davis, N. Musolino, M. Mack, C.A. Power, and A.E. Proudfoot ***Prot. Eng. Des. Sel.*** (2012) Properties of 7ND-CCL2 are modulated upon fusion to Fc. **25** 213-22.
9. V. Ramamurthy et al. ***Structure*** (2012) Structures of adnectin/protein complexes reveal an expanded binding footprint. **20** 259-69.
10. J.H. Davis, C. Aperlo, Y. Li, E. Kurosawa, Y. Lan, K-M. Lo, and J. S. Huston ***Prot. Eng. Des. Sel.*** (2010) SEEDbodies: fusion proteins based on strand-exchange engineered

domain (SEED) CH₃ heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. **23** 195-202. (Cover picture)

11. J.M. Carothers, J.H. Davis, J.J. Chou, and J.W. Szostak **RNA** (2006) Solution structure of an informationally complex high-affinity RNA aptamer to GTP. **12** 567-79.
12. J.M. Carothers, S.C. Oestreich, J.H. Davis, and J.W. Szostak **J Am Chem Soc.** (2004) Informational complexity and functional activity of RNA structures. **126** 5130-37.
13. J.H. Davis and J.W. Szostak **Proc. Natl Acad Sci USA** (2002) Isolation of high-affinity GTP aptamers from partially structured RNA libraries. **99** 11616-21.
14. S.S. Jaswal, J.L. Sohl, J.H. Davis, and D.A. Agard . **Nature** (2002) Energetic landscape of alpha-lytic protease optimizes longevity through kinetic stability **415:6869** 343-346.
15. J.H. Davis and D.A. Agard **Biochemistry** (1998) Relationship between enzyme specificity and the backbone dynamics of free and inhibited α -lytic protease. **37** 7696-7707.
16. J.H. Davis, D.A. Agard, T.M. Handel, & V.J. Basus **J Biomol. NMR** (1997) Alterations in chemical shifts and exchange broadening upon peptide boronic acid inhibitor binding to α -lytic protease. **10** 21-27.
17. J.H. Davis **J. Biomol. NMR** (1995) An optimized, gradient-enhanced refocused HSQC: applications in 2- and 3-D NMR and in deuterium exchange experiments. **5**, 433-437.
18. J.H. Davis, E.K. Bradley, G.P. Miljanich, L. Nadasdi, J. Ramachandran, & V.J. Basus **Biochemistry** (1993) Solution structure of ω -conotoxin GVIA using 2-D NMR spectroscopy and relaxation matrix analysis. **32**, 7396-7405.
19. R.L. Bernstein, W.C. Hyun, J.H. Davis, M.J. Fulwyler, & H.A. Pershadsingh **Cytometry** (1989) Flow cytometric analysis of mature adipocytes. **10**, 469-474.

ISSUED PATENTS

1. J.H. Davis and N.M. Marshall Orthogonal mutations for heterodimerization. U.S. patent number 12,312,418
2. D. Lipovsek and J.H. Davis Fibronectin based scaffold proteins. U.S. patent number 11,447,538
3. T. S. Mitchell... J. H. Davis et al. Serum albumin-binding fibronectin type III domains. U.S. patent number 11,203,630
4. M.R. Krystal, D.L. Wensel, J. Davis Polypeptides targeting HIV fusion. U.S. patent number 11,155,602
5. M. Struthers, J. Davis, M. Doyle, & P. Madia. Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use. U.S. patent number 10,787,494 and 11,359,000
6. R. Camphausen, A. Saeed-Kothe, J. Davis, T.S. Mitchell Fc fusion proteins comprising novel linkers or arrangements EP patent number 3,144,320B9
7. J. Davis et al. Fibronectin binding domains with reduced immunogenicity U.S. patent number 10,604,556

8. J. Davis et al. Fibronectin binding domains with reduced immunogenicity U.S. patent number 10,464,995
9. M. Super, J.H. Davis, P.A. Stein Methods of Use Of Anti-CD19 antibodies with reduced immunogenicity. US patent number 10,072,092
10. R. Camphausen, J. Davis, et al. Fibronectin based scaffold domains proteins that bind PCSK9 U.S. patent number 9,856,309
11. J. Davis et al. Fibronectin binding domains with reduced immunogenicity U.S. patent number 9,765,132
12. J. Davis et al. Fibronectin binding domains with reduced immunogenicity U.S. patent number 9,522,951
13. J.H. Davis, J.S. Huston, Engineered heterodimeric protein domains. US patent number 9,505,848
14. R. Camphausen, A. Saeed-Kothe, J.H. Davis, T.S. Mitchell Fc fusion proteins comprising novel linkers or arrangements. U.S. patent number 9,469,676
15. J. Davis et al. Fibronectin binding domains with reduced immunogenicity U.S. patent number 9,416,170
16. R. Camphausen, J.H. Davis, et al. Fibronectin based scaffold domain proteins that bind PCSK9. U.S. patent number 9,234,027
17. M. Super, J.H. Davis, P.A. Stein Anti-CD19 antibodies with reduced immunogenicity. US patent number 8,957,195
18. J.H. Davis, J.S. Huston, Engineered heterodimeric protein domains. US patent number 8,871,912
19. M. Super, J.H. Davis, P.A. Stein Anti-CD19 antibodies with reduced immunogenicity. US patent number 8,691,952
20. R. Camphausen, J.H. Davis, et al. Fibronectin based scaffold domain proteins that bind to PCSK9. U.S. patent number 8,420,098

PATENT APPLICATIONS

1. J.H. Davis, N.M. Marshall, Multispecific binding agents that target b7h3 and gd2 and uses thereof. WO2023245022A2 published Dec 21 2023, ref. number US2023/068384
2. J.H. Davis, N.M. Marshall, Orthogonal mutations for heterodimerization. EP4259194A1 published Oct 18, 2023
3. G. B. Banks, J. H. Davis, P. C. Levesque, Miniaturized dystrophins having spectrin fusion domains and uses thereof. Utility published Dec 21 2023, ref. number 20230407331
4. G. Banks, J.H. Davis, P.C. Levesque, Miniaturized dystrophins and uses thereof. Utility published Dec 30 2021, ref. Number 202110403947
5. J.H. Davis and J. S. Huston Engineered heterodimeric protein domains Utility published May 25, 2017 ref. number 20170145078

6. R. Camphausen, A. Saeed-Kothe, J.H.Davis, and T.S. Mitchell Fc fusion proteins comprising novel linkers or arrangements Utility published Dec 29 2016, ref. number 20160376346
7. R. Camphausen et al. Fibronectin based scaffold domain proteins that bind PCSK9 Utility published June 9 2016, ref number 20160159883
8. D. Lipovsek and J.H. Davis Fibronectin based scaffold proteins Utility published Dec 17, 2015, ref. Number 20150361159
9. M. Super, J.H. Davis, P.A. Stein. Methods of use of anti-CD19 antibodies with reduced immunogenicity Utility published Nov 12, 2015, ref. number 20150322159
10. J.H. Davis & J.S. Huston Engineered heterodimeric protein domains Utility published Apr 16 2015, ref. number 20150104865
11. J.H. Davis. Artificial Protein Scaffolds. Utility published Feb 4, 2010, ref. Number 20100029499
12. J.H. Davis. Compounds and methods for fluorescently labeling nucleic acids. Utility published Nov 13, 2003, ref. number 20030211516.